Close
Close
Finance News

Corbus Pharmaceuticals to Present at the 2018 RBC Capital Markets Global Healthcare Conference

2.76923076923
2.8 from 13 votes
Thursday, February 15, 2018

NORWOOD, MA - Corbus Pharmaceuticals Holdings, Inc., a clinical-stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will present in a fireside chat at the 2018 RBC Capital Markets Global Healthcare Conference on Thursday, February 22nd at 3:35 p.m. EST in New York, NY.

Dr. Cohen will discuss the Company's four clinical development programs in diffuse cutaneous systemic sclerosis ("SSc"), cystic fibrosis ("CF"), skin-predominant dermatomyositis ("DM") and systemic lupus erythematosus ("SLE") for lenabasum, its novel, synthetic oral endocannabinoid-mimetic drug that is designed to resolve chronic inflammation and halt fibrosis.

Corbus' Phase 3 RESOLVE-1 study assessing the efficacy and safety of lenabasum for the treatment of SSc and its Phase 2 study of lenabasum for the treatment of SLE are currently underway. Additionally, the Company expects to initiate its next phase of development of lenabasum for the treatment of DM in the second half of 2018. Corbus recently announced the launch of its Phase 2b multicenter, double-blinded, randomized, placebo-controlled study of lenabasum for the treatment of CF that will enroll approximately 415 patients with CF who are at least 12 years of age and at increased risk for pulmonary exacerbations. In support of the Phase 2b study, Corbus received a Development Award for up to $25 million from the Cystic Fibrosis Foundation. The Company expects the first patient to be dosed in the Phase 2b CF study this quarter.

A live audio webcast of the fireside chat will be accessible on the Events page of the Investors section of Corbus website, www.corbuspharma.com, and will be archived on the Company's website for 90 days following the event.

About Lenabasum
Lenabasum (formerly known as anabasum) is a synthetic, oral, small-molecule, selective cannabinoid receptor type 2 (CB2) agonist that preferentially binds to CB2 expressed on activated immune cells and fibroblasts. CB2 activation triggers physiologic pathways that resolve inflammation, speed bacterial clearance and halt fibrosis. CB2 activation also induces the production of specialized pro-resolving lipid mediators that activate an endogenous cascade responsible for the resolution of inflammation and fibrosis, while reducing production of multiple inflammatory mediators. Through activation of CB2, lenabasum also is designed to have a direct effect on fibroblasts to halt tissue scarring. Lenabasum is believed to induce resolution rather than immunosuppression by triggering biological pathways to turn "off" chronic inflammation and fibrotic processes. Lenabasum has demonstrated promising potency in preclinical models of inflammation and fibrosis. Preclinical and human clinical studies have shown lenabasum to have a favorable safety, tolerability and pharmacokinetic profile. Further, the drug has demonstrated clinical benefit and positive impact on inflammatory and immunological markers in Phase 2 studies in diffuse cutaneous systemic sclerosis, dermatomyositis and cystic fibrosis.

About Corbus
Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.

Contact
Institutional Investor Inquiries
Ted Jenkins, Senior Director, Investor Relations and Communications
Corbus Pharmaceuticals, Inc.
Phone: +1 (617) 415-7745

All Other Investor Inquiries
Jenene Thomas
Jenene Thomas Communications, LLC
Phone: +1 (908) 938-1475

Media Contact
Eliza Schleifstein
Scient Public Relations
Phone: + 1 (917) 763-8106

Source: Corbus Pharmaceuticals Holdings, Inc.
2.76923076923
2.8 from 13 votes
Free Newsletter
Related Videos